WX ATU is a CDMO company focused on cell and gene therapy (Cell & Gene Therapy, CGT)领域, committed to providing一站式 solutions from research and development to commercial production for global clients.

The company has built a comprehensive technology and production platform covering plasmids, viral vectors, and cell products, with production facilities meeting GMP requirements and a robust quality management system that supports early-stage research, IND applications, clinical production, and commercial scale-up.

With mature platform technologies, systematic CMC strategies, and extensive regulatory support experience, Wuxi BioGene has provided services to multiple innovative biopharmaceutical companies and has successfully passed audits by domestic and international regulatory authorities and clients.

We are committed to compliance as the foundation, quality as the core, and efficiency as the advantage, striving to become a trusted partner for global innovative therapies.